Abstract

The Cancer Center strategic planning process identified the recruitment of new faculty as the most important priority for the past funding period, and it remains the most important priority for the proposed future funding period. Accordingly Cancer Center development funds have been used to support 11 new investigators, while Wistar Institute funds have underwritten pilot projects and bridged investigators who have developed research funding shortfalls due to delays in getting grants renewed. Over the past funding cycle, developmental funds have been used to support part of the direct research costs of new recruits for up to three years following their arrival. We have used $1,508,942 in developmental funds and these investigators are well on their way to establishing independent research programs. They have received funding for 14 NIH or Department of Defense grants, 25 foundation grants, and three American Cancer Society grants, among a total of almost 50 total awards, amounting to $18,266,554 in total extramural grant dollars. The Cancer Center has been able to make progress in achieving its strategic goals in the past funding period because of developmental funds provided by both the Institute and the CCSG.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA010815-42
Application #
8233465
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-03-01
Budget End
2012-02-29
Support Year
42
Fiscal Year
2011
Total Cost
$435,923
Indirect Cost

  Institution

Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104

  Publications

Li, Heng; Wang, Zhize; Xiao, Wei et al. (2018) Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients. Mod Pathol 31:198-208
Shastrula, Prashanth K; Rice, Cory T; Wang, Zhuo et al. (2018) Structural and functional analysis of an OB-fold in human Ctc1 implicated in telomere maintenance and bone marrow syndromes. Nucleic Acids Res 46:972-984
Duperret, Elizabeth K; Trautz, Aspen; Ammons, Dylan et al. (2018) Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice. Clin Cancer Res 24:1190-1201
Heppt, Markus V; Wang, Joshua X; Hristova, Denitsa M et al. (2018) MSX1-Induced Neural Crest-Like Reprogramming Promotes Melanoma Progression. J Invest Dermatol 138:141-149
Wu, Shuai; Fatkhutdinov, Nail; Fukumoto, Takeshi et al. (2018) SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells. Nat Commun 9:4116
Ecker, Brett L; Kaur, Amanpreet; Douglass, Stephen M et al. (2018) Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis. Cancer Discov :
Abdel-Mohsen, Mohamed; Kuri-Cervantes, Leticia; Grau-Exposito, Judith et al. (2018) CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. Sci Transl Med 10:
Fukumoto, Takeshi; Magno, Elizabeth; Zhang, Rugang (2018) SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications. Mol Cancer Res 16:1819-1825
Cañadas, Israel; Thummalapalli, Rohit; Kim, Jong Wook et al. (2018) Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med 24:1143-1150
Basu, Subhasree; Gnanapradeepan, Keerthana; Barnoud, Thibaut et al. (2018) Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1?. Genes Dev 32:230-243

Showing the most recent 10 out of 741 publications